GlassScriptPhysician profile
Pooja Shankar
NPI 1093249906
$1,826.60
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $44.57 · 2021: $195 · 2022: $531 · 2023: $421 · 2024: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $348.63 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $306.19 | 2021-2024 | Ubrelvy, Qulipta |
| Abbott Laboratories | $145.83 | 2021-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $143.17 | 2021-2024 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $121.79 | 2019 | |
| Janssen Pharmaceuticals, INC | $90.50 | 2022-2024 | Xarelto |
| Amgen INC. | $74.92 | 2020-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $71.38 | 2022-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $63.19 | 2022-2024 | |
| Astellas Pharma US INC | $55.49 | 2023-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $53.01 | 2022-2024 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $52.88 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.03 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $48.32 | 2021-2024 | Breztri, Farxiga |
| Curonix LLC | $41.82 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $40.95 | 2022-2023 | Nexletol |
| Exact Sciences Corporation | $36.54 | 2023-2024 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $19.77 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $19.07 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $15.73 | 2022 | |
| Amarin Pharma, INC. | $14.39 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.00 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pooja Shankar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.